Third-generation EGFR-TKI (double-dose)
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for Third-generation EGFR-TKI (double-dose), covering 2026-04-23 to 2026-04-23. Get the full timeline:
Most recent: Clinical Trial Update: Double-Dose Third-Generation EGFR-TKI Plus Bevacizumab and Intrathecal Chemotherapy for Refractory Leptomeningeal Metastatic NSCLC: A Phase II Study [NA]